<DOC>
	<DOCNO>NCT01164761</DOCNO>
	<brief_summary>The purpose study - To characterize pharmacokinetic profile Ramipril 10 mg capsule relative ALTACE @ 10 mg capsule healthy , adult , human , male subject fast condition assess bioequivalence . - To monitor safety subject .</brief_summary>
	<brief_title>Bioavailability Study Ramipril 10 mg Capsules Dr. Reddy 's Laboratories Limited Under Fasting Conditions</brief_title>
	<detailed_description>A Two-way open label crossover experimental evaluation relative bioavailabilities Ramipril 10 mg capsule Dr.Reddy 's Laboratories ALTACE @ 10 mg capsule King Pharmaceuticals healthy adult human male subject fast condition .</detailed_description>
	<mesh_term>Ramipril</mesh_term>
	<criteria>1 . Healthy male 18 45 year age ( inclusive ) live around Ahmedabad city western part India . 2 . Having Body Mass Index ( BMI ) 18.5 24.9 ( inclusive ) , calculate weight kg/height m2 3 . Not significant disease clinically significant abnormal finding screen , medical history , physical examination , laboratory evaluation , ECG Xray recording . 4 . Able comply study procedure , opinion investigator . 5 . Able give write consent participation trial . 1 . Known hypersensitivity idiosyncratic reaction ramipril relate drug . 2 . Any disease condition might compromise haemopoietic , renal , hepatic , endocrine , pulmonary , central nervous , cardiovascular , immunological , dermatological , gastrointestinal body system . 3 . Use medicine within 14 day prior start study . In case subject selection discretion Principal Investigator/Medical expert 4 . Any history presence asthma ( include aspirin induce asthma ) nasal polyp . 5 . A recent history alcoholism &lt; 2 year ) moderate ( 180 mL/day ) alcohol use , consumption alcohol within 48 hr prior receive IP . 6 . Smokers , smoke 10 cigarettes/day inability abstain smoking study . 7 . The presence clinically significant abnormal laboratory value screen . 8 . Use recreational drug history drug addiction test positive prestudy drug scan . 9 . History psychiatric disorder . 10 . A history difficulty donate blood . 11 . Donation blood ( 1 unit 350 mL ) within 90 day prior receive first dose IP . Note : In case , blood loss ≤ 200 mL , subject may enrol 60 day blood donation . 12 . A positive hepatitis screen include hepatitis B surface antigen , Anti HCV AntiHAV antibody . 13 . A positive test result HIV antibody and/or syphilis . 14 . The receipt investigational drug product , participation drug research study within period 90 day prior first dose IP ( Elimination halflife study drug take consideration inclusion subject study ) . Note : If subject participate study blood loss ≤ 200 mL , subject dose completion 60 day last sample previous study . 15 . An unusual diet , whatever reason ( e.g . lowsodium ) , four week prior receive IP throughout subject ' participation study . In case subject selection discretion Principal Investigator/Medical expert . 16 . Sitting blood pressure le 110/70 mm Hg pulse rate le 60 100 beat per minute screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Bioavailability</keyword>
	<keyword>Crossover</keyword>
	<keyword>Ramipril</keyword>
</DOC>